RightAnswer Knowledge Solutions Search Results for Panitumumab

New Search  |  Search Results (Panitumumab)  |  Index of Example Chemical Results Pages
register now
RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.

A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
  • Chemical Identification
  • Environmental Hazards
  • First Aid/Medical Treatment
  • Handling/Storage/Shipping/Waste Management
  • Personal Protection
  • Physical Hazards/Corrective Response Actions
  • Physical/Chemical Properties
  • Regulatory/Standards/Labels
  • Report Abstracts and Studies
  • Reproductive Risk
  • Toxicology/Health Hazards/Exposure
Example of Acute Exposure data from MEDITEXT.

RightAnswer Proprietary Data Sources:

HAZARDTEXT™ Documentshelp
MEDITEXT® Documentshelp

All Other Data Sources:

LOLI® Listingshelp
RTECS® Registryhelp
TERIS Documentshelp

ChemID External Links:

Other Government Links Searched via RegsKnowledge:

State Environmental Regulationshelp
CFR Regulationshelp

Example Content from MEDITEXT for Panitumumab:

Please note: this is an extract of information from a larger document. Full document and details are available by subscription.


  1. USES: Used for the treatment of epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
  1. PHARMACOLOGY: Panitumumab is a recombinant, human IgG2 kappa monoclonal antibody and binds to human EGFR specifically, on both normal and tumor cells. Panitumumab competitively inhibits the binding of ligands for EGFR.
  1. EPIDEMIOLOGY: Overdoses are rare.
    1. ADVERSE EFFECTS: COMMON: Dermatologic effects develop in most (90%) patients, and include: erythema (65%), acneiform dermatitis (57%), pruritus (57%), nail changes (29%), paronychia (25%), exfoliation (25%), skin fissures (20%), and dry skin (10%). Other adverse effects include: hypomagnesemia (38%), fatigue (26%), abdominal pain (25%), nausea/vomiting (23% and 19%), diarrhea (21%), constipation (21%), and cough (14%). Less common adverse effects include: hyperglycemia, hypokalemia, hypocalcemia, cheilitis, ocular toxicities (e.g. conjunctivitis, ocular hyperemia, increased lacrimation, eye/eyelid irritation, and eyelash growth), thrombophlebitis, bone pain, back pain, asthenia, dyspnea, and infectious complications. Rare, but serious complications include pulmonary fibrosis and infusion-related toxicity (e.g. anaphylactoid reactions, bronchospasm, hypotension).
    1. MILD TO MODERATE TOXICITY: Skin toxicity, diarrhea, dehydration and fatigue have been reported in patients receiving doses up to approximately twice the recommended therapeutic dose (12 mg/kg).
    1. SEVERE TOXICITY: No severe toxicity were reported following doses of approximately twice the recommended therapeutic dose (12 mg/kg).
© 2011-2021 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.